Summit Therapeutics Share Discussion Threads

[waterloo01] 11/12/2018 12:58

It's what happens before Sept 19 that's of more interest. They wouldn't say they are on track to start the phase 3 unless they were confident they will fill the funding gap. Best guess is either selling further rights and or grants.

Discuva seems to be producing some great targets and newsflow.

We know antibiotics are less than 'hot' but that can change.

[multiplural] 11/12/2018 12:54

I don't think Summit will bring a drug to market. They will search for the value inflexion point and sell to a larger corporation that can market their developed drugs.

[lagosboy] 11/12/2018 12:30

What happens after Sept 2019?

I have to admire your resilience and loyalty, but how anyone can be happy with a market cap of £13 m is beyond me.

The grants and cash are a mere drop in the ocean in comparison to what is needed to bring a drug to market.

[waterloo01] 11/12/2018 12:07

£13m and on track for 1st Q RDZ trials. Cash runway through to Sept 19.

Happy with that given the market cap is £13m!

[football] 11/12/2018 12:05

12 million + in the bank and Phase II trial starting very soon may have a good 2019 if the money doesn't run out first

[solomon] 11/12/2018 11:49

counting down to the Q3 results

[multiplural] 10/12/2018 21:44

Bid might be coming our way, unfortunately.
I guess that if someone now bid double up it would fly, and that is a shame imo.

[buywell3] 10/12/2018 21:25

Yanks are suckers for BioTechs

[lagosboy] 10/12/2018 21:23

But its 19% of not very much and its just traders punting - alright for new punters but little consolation for long term holders such as me.

[buywell3] 10/12/2018 20:49

Summit - Climbing to new heights


Name change required

Summit - Slumping to new Lows

[waterloo01] 10/12/2018 19:48

Up 19% on Nasdaq. Sense finally prevails. I added a few at 18.5p today. Bargain.

[waterloo01] 10/12/2018 18:41

At least Nasdaq is up in anticipation of the results tomorrow.

[lagosboy] 07/12/2018 22:17

RDZ is not a potential blockbuster. If peak sales could be around $1 billion why are we in the current predicament, mucking around buying Discuva Platform to expand the pipeline.

There are also very significant costs post P3 if that delivers a successful outcome. Summ cannot bring a drug to market without a licence partner.

[waterloo01] 07/12/2018 18:09

I'll agree that antibiotics are currently not in favour and hence why grants. As for $62m being 'small fry' well I take your small fry any day. Non dilutive money. Both phase 3's will cost around $100m, so the gap is, in your terms, tiny.

RDZ, even as an unloved antibiotic should still have peak sales around $1bn.

[lagosboy] 07/12/2018 17:46

waterloo- you are missing the point - its the cost of getting these drugs to market and the fact that there is very little interest in new antibiotics generally from big pharma due to commercial considerations..

The $19m of cash and $62 m in grants which will be not be unconditional and are pretty small fry in the bigger scheme of things.

If the pipeline is so special why were Summable to pick it up for a song?

I am just fed up that Glyn did not jump on some funding opportunities much earlier instead of protecting his position. He has backed Sum into a corner.

[waterloo01] 07/12/2018 16:37

Nuts isn't it. If you wanted to IPO a new company that has around $19m in cash, $62m in non dilutive grant funding have a drug ready to go into phase 3 and an interesting pipeline behind it that has also attracted grant funding of $4.5m

On sale today for $16m.

[multiplural] 07/12/2018 16:29

I bought 5.000 ADS yesterday around 1.28 just to see it at 1,17 today equal to 18,5p. Unbelieveable, can't help to think what it would cost to get here if one had to start the research they have and be at the present level.

[waterloo01] 07/12/2018 16:04

I think I might be the only buyer around at the moment ahead of Tuesday's results. Been that way most of the week. The market must be expecting bad news. I sincerely hope the results and comment will prove the market has under appreciated it's value!

[waterloo01] 06/12/2018 14:00

Lagosboy, we know the two phase 3 trials will cost about $100m. Barda have committed $42m so far with another $20m available. Plus they have some cash coming on for the S. American rights and if they sold off other rights ex USA, it would be pretty much fully funded and with zero dilution.

Edit: I expect cash should be around £15m (they had £17m but should have some tax credits and other income). Current market cap £13.57m.

[football] 06/12/2018 13:30

Spellcheck is okay if it's got a clue what you're saying to start off with, best voice software I use is the Google one when sending text messages you just hold the ; tab and a microphone pops up so you can talk away would say it's almost 100% and it's a a lot faster than typing.

Said it before the only reason I invested here was because they are not like normal biotech companies with just the one shot at getting a drug which is like playing Russian roulette here summit had three or four drugs possibly on the go so if the first one failed you had another go a few years later down the line and not all was lost even though it seemed like it at present

[lagosboy] 06/12/2018 13:27

Its quite normal for a small pharma to trade below its cash value.

There seems to be little or no appreciation of how money is needed to bring a drug to market even if it gets through the trials. That's the cost that any suitor would need to consider, not the petty cash Summ has on its balance sheet which will be expended over the next few months anyway.

I have no idea how Summ can stat trials without the funding to see them through to conclusion.

Buying a small pharma on AIM run by a CEO renown for looking after himself and screwing up at big time at Antisoma is madness. Slightest pop and I am out altogether here.

[waterloo01] 06/12/2018 12:55

Ditto, also a dyslexic. Spell check usually saves me these days.

[chrisatrdg] 06/12/2018 12:41

Hi football - I was once 'Interim Finance Manager' of the BDA (British Dyslexic Society) not a bad club to be in & have the ability to think outside the box & many other positive attributes.